Primary Cutaneous T Cell Lymphoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for primary cutaneous t cell lymphoma. 201 active patents protecting 10 drugs from 6+ originators. First major cliff: 2027. Daily refresh.

10
Approved drugs
201
Active US patents
64/100
Avg vulnerability
$2.9B
Annual revenue covered

Originators in Primary Cutaneous T Cell Lymphoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Teva Pharm 118 patents Merck & Co. 44 patents Generic (originally Schering) 33 patents Eurofarma 4 patents Padagis Us 1 patents Taro 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating primary cutaneous t cell lymphoma. Each bar = one year. Y-axis scaled to peak year (40 patents).

3
26
11
27
6
28
9
30
40
31
6
32
4
33
31
34
15
35
9
36
3
37
1
38
25
39
28
40
8
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cutivate
FLUTICASONE PROPIONATE
 Teva Pharm 118 58 $69M 2026-08-26
Elocon
MOMETASONE FUROATE
 Merck & Co. 22 44 — 2026-11-29
Diprolene
BETAMETHASONE DIPROPIONATE
 Merck & Co. 20 62 — 2027-09-27
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Derma-Smoothe/Fs
FLUOCINOLONE ACETONIDE
 Eurofarma 4 72 — 2027-08-12
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03
Zolinza
VORINOSTAT
 Merck & Co. 2 52 — 2027-03-11
Verdeso
DESONIDE
 Padagis Us 1 80 $2.8B 2027-08-13
Topicort
DESOXIMETASONE
 Taro 1 83 — 2028-09-01

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9849027 Derma-Smoothe/Fs method of use 88 2028-11-07
7998108 Derma-Smoothe/Fs method of use 83 2028-01-12
12083270 Cutivate method of use 81 2031-04-04
7500444 Cutivate other 80 2026-08-26
7500444 Cutivate other 80 2026-08-26
8460641 Verdeso method of use 80 2027-08-13
8168218 Deltasone method of use 80 2028-01-07
8450372 Zolinza method of use 80 2028-03-18
8277780 Topicort method of use 80 2028-09-01
9504699 Deltasone method of use 75 2027-08-03

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12303635 Elocon composition of matter 0 2039-04-08
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10406332 Elocon formulation 25 2034-03-13
7456219 Zolinza composition of matter 27 2027-03-11
10799642 Decadron formulation 31 2032-05-11
8763222 Elocon formulation 31 2032-02-08
8409606 Decadron formulation 31 2030-05-14
11679210 Elocon formulation 33 2038-09-03
10561672 Elocon formulation 33 2034-09-04

Related